YMAB

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

Y-mAbs Announces Update on SADA Technology

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2021 Results - Earnings Call Transcript

Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer

Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q4 2020 Results - Earnings Call Transcript

Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares